Clinical Trial Update: A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B Subjects [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating AL-3778 in combination with peginterferon alpha-2a for chronic hepatitis B has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• AL-3778
• Peginterferon alfa-2a (peginterferon alfa-2a)

Snippet

Sponsor: Alios Biopharma Inc. | Conditions: Hepatitis B, Chronic | Phase 2 | Status: WITHDRAWN